Featured News
More News
FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices
The U.S. Food and Drug Administration today permitted marketing of the Dexcom G6 integrated continuous glucose monitoring (iCGM) system for determining blood glucose (sugar) levels in children aged two and older and adults with diabetes.
Breaking down diabetes: New controversy on blood sugar lowering
Inside the community of diabetes experts and organizations, a heated debate is raging. The debate centers around blood sugar levels, but, like so many divisions in our society, it is really about much more.
Breaking down diabetes: Insulin, unwelcome, but underutilized
During my medical training in the 1990s, I was taught that insulin was a last resort after patients with Type 2 diabetes had “failed” oral medications, meaning their blood sugar remained worryingly high.
Using antibody in treatment of ‘bubble boy disease’ shows early promise
In a clinical trial, participants were given an antibody to CD117, a cell surface marker, in an effort to wipe out their defective blood stem cells without high-risk chemotherapy or radiation.
Breaking down diabetes: Drugs for diabetes, starting with the best — metformin
A huge assortment of 100 medications are available to treat high blood sugar in Type 2 diabetes, including two historical breakthrough drugs, insulin and metformin.
Following events at the ADA Scientific Sessions in June, a number of concerns raised regarding the ADA's professional section remain unresolved. As a result, a boycott of ADA activities has been initiated by leading figures in diabetes research. The text below includes relevant hyperlinks with further information. Those who wish to review the petition and consider whether to sign it may do so at the links provided. This information is being shared for member awareness.